Trial Information
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724